Publications by authors named "Louie Tirador"
Background: Recombinant protein vaccines are vital for broad protection against SARS-CoV-2 variants. This study assessed ReCOV as a booster in two Phase 2 trials.
Research Design And Methods: Study-1 involved subjects were randomized (1:1:1) to receive 20 μg ReCOV, 40 μg ReCOV, or an inactivated vaccine (COVILO®) in the United Arab Emirates.
Article Synopsis
- ReCOV is a recombinant protein vaccine designed to provide broad protection against various SARS-CoV-2 variants, with studies conducted in New Zealand and the Philippines during phases I and II.
- The studies were randomized, double-blind, placebo-controlled trials involving healthy adults who received two doses of the vaccine 21 days apart, focusing on safety and immunogenicity outcomes.
- Results showed that while the ReCOV group experienced a higher incidence of mild to moderate adverse events in phase I, both groups had similar rates in phase II; the vaccine produced robust neutralizing antibodies against the virus, peaking 14 days after the second dose.
Background: The live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine (dNS1-RBD, Pneucolin; Beijing Wantai Biological Pharmacy Enterprise, Beijing, China) confers long-lasting and broad protection in animal models and is, to our knowledge, the first COVID-19 mucosal vaccine to enter into human trials, but its efficacy is still unknown. We aimed to assess the safety and efficacy (but not the immunogenicity) of dNS1-RBD against COVID-19.
Methods: We did a multicentre, randomised, double-blind, placebo-controlled, adaptive design, phase 3 trial at 33 centres (private or public hospitals, clinical research centres, or Centre for Disease Control and Prevention) in four countries (Colombia, Philippines, South Africa, and Viet Nam).
Atrial fibrillation (AF) is the most common heart arrhythmia. Untreated AF incurs a considerable burden of stroke and associated healthcare costs. Asians have AF risk factors similar to Caucasians and a similarly increased risk of AF-related stroke; however, with a vast and rapidly ageing population, Asia bears a disproportionately large disease burden.
View Article and Find Full Text PDF